Overactive Bladder Medication

Overactive Bladder Medication Market Outlook

The global Overactive Bladder (OAB) Medication market is projected to reach approximately USD 3.8 billion by 2035, growing at a CAGR of around 5.6% from 2025 to 2035. The increase in the prevalence of overactive bladder conditions, rising awareness among patients regarding available treatments, and the availability of advanced pharmacological therapies are significant factors driving this growth. Moreover, lifestyle changes, increasing stress levels, and the aging population are also contributing to the rising incidence of OAB, creating a growing demand for effective treatment options. The integration of innovative drug delivery systems and the focus on developing new therapies with improved safety and efficacy profiles are further anticipated to enhance market growth. As such, the ongoing research and development efforts in the pharmaceutical sector are likely to introduce more effective medications, thereby expanding the market capacity.

Growth Factor of the Market

The Overactive Bladder Medication market is primarily influenced by several driving factors that bolster its growth trajectory. One of the foremost factors is the increasing prevalence of OAB, which is more common among the elderly population; this demographic shift is prompting healthcare providers to seek effective treatment solutions. Furthermore, technological advancements in drug formulation and delivery systems are enhancing the therapeutic options available for patients, making it easier to manage symptoms associated with OAB. The rising awareness of OAB and its impact on quality of life has led to increased patient engagement, prompting more individuals to seek medical advice and treatment. Additionally, there is a significant rise in healthcare expenditure and the availability of health insurance, making medications more accessible to a broader range of patients. Lastly, the continuous innovation in drug development, including the advent of agents like mirabegron, is instrumental in transforming the therapeutic landscape for OAB management.

Key Highlights of the Market

• The global market is expected to grow at a CAGR of 5.6% from 2025 to 2035.
• North America is the largest market segment, accounting for over 40% of the total market share.
• Anticholinergics currently dominate the product type segment.
• Online pharmacies are emerging as a significant distribution channel due to rising digital healthcare adoption.
• The neurogenic overactive bladder application segment is expected to witness the highest growth rate.

By Product Type

Anticholinergics:

Anticholinergics account for the largest share in the Overactive Bladder Medication market owing to their effectiveness in reducing bladder muscle spasms and increasing bladder capacity. These medications work by blocking the action of acetylcholine, a neurotransmitter that stimulates bladder contractions, thus providing symptomatic relief for patients. Commonly prescribed anticholinergics include Oxybutynin and Tolterodine, both of which have a long-standing history of clinical use. The availability of these medications in various forms, such as extended-release tablets and transdermal patches, enhances patient compliance. However, the potential side effects, including dry mouth and constipation, can limit patient adherence, prompting ongoing research into developing newer agents with improved tolerability and fewer adverse effects.

Mirabegron:

Mirabegron represents a novel class of medications known as beta-3 adrenergic agonists, which have gained attention for their ability to relax the bladder muscle and enhance bladder storage capacity. This medication works distinctly compared to traditional anticholinergics, making it a valuable option for patients who cannot tolerate these older therapies due to side effects. Mirabegron has been shown to significantly improve symptoms associated with OAB, such as urgency and frequency of urination, while having a more favorable side effect profile. The growing acceptance of mirabegron among healthcare providers and patients is expected to contribute to its increasing market share, particularly as clinical guidelines evolve to incorporate its use more prominently for OAB management.

Alpha Blockers:

Alpha blockers are another type of medication utilized in the management of Overactive Bladder, primarily focusing on improving urinary flow by relaxing the muscles in the prostate and bladder neck. Though they are not specifically designed for OAB, alpha blockers like Tamsulosin are often prescribed to male patients experiencing urinary symptoms associated with benign prostatic hyperplasia (BPH) concurrently with OAB. The dual management of BPH and OAB may drive the adoption of alpha blockers in clinical settings, especially among older male patients. However, the market share of alpha blockers in the OAB segment remains smaller compared to anticholinergics and mirabegron, primarily due to the growing preference for more targeted therapies.

Botox:

Botulinum toxin injections, commonly referred to as Botox, have emerged as a treatment option for patients with refractory overactive bladder who do not respond adequately to oral medications. This treatment involves injecting Botox directly into the bladder muscle, leading to a reduction in involuntary contractions and an increase in bladder capacity. The efficacy of Botox in managing OAB symptoms has been supported by numerous clinical trials, making it a valuable alternative for patients seeking relief. However, the high cost and the need for repeat injections, which can be inconvenient, may limit its widespread adoption. Nevertheless, as awareness of this injectable treatment modality increases, it is anticipated to carve out a more significant share of the overall OAB market.

Others:

The "Others" category encompasses various emerging therapies and alternative medications that are being explored for managing overactive bladder symptoms. This includes herbal remedies, dietary supplements, and off-label use of certain medications that may provide symptomatic relief. The interest in natural and holistic approaches to healthcare is driving some patients to seek these alternative options. While the market impact of these products is currently minimal, ongoing research into their efficacy and safety profiles may foster greater acceptance and utilization in the future. As patient preferences evolve, this segment may offer opportunities for novel therapies to address specific needs and preferences of various patient populations.

By Application

Idiopathic Overactive Bladder:

Idiopathic Overactive Bladder refers to cases of OAB without an identifiable underlying condition, which constitutes a significant portion of the overall market. Patients suffering from idiopathic OAB often experience a range of debilitating symptoms including urgency, frequency, and nocturia, which can severely impact their quality of life. The growing understanding of this condition and the development of effective pharmacological treatments have led to a notable increase in diagnosis and treatment rates. The idiopathic OAB application segment is expected to witness steady growth, driven by rising awareness campaigns and improvements in healthcare access, enabling more patients to seek treatment and management options tailored to their specific needs.

Neurogenic Overactive Bladder:

Neurogenic Overactive Bladder is characterized by bladder dysfunction arising from neurological conditions such as multiple sclerosis, spinal cord injuries, and stroke. This specific application segment is gaining traction as healthcare providers increasingly recognize the need for specialized management strategies for patients with neurological impairments. The complexity of managing neurogenic OAB often requires a multi-faceted approach, including the use of medications, pelvic floor therapy, and sometimes surgical interventions. As the incidence of neurological conditions continues to rise, the neurogenic OAB segment is anticipated to expand significantly, driven by the demand for targeted therapeutic options that can effectively address the unique challenges faced by these patients.

Others:

The "Others" application segment includes various less common causes of overactive bladder symptoms that do not fall under idiopathic or neurogenic classifications. This may encompass conditions such as urinary tract infections, bladder infections, or side effects from certain medications. Although this segment represents a smaller market share compared to idiopathic and neurogenic categories, it remains significant as healthcare practitioners strive to provide comprehensive treatment options for all patients, regardless of the underlying cause of their OAB symptoms. The ongoing research into the various etiologies of OAB and their appropriate management is expected to enhance the understanding and treatment of this diverse population.

By Distribution Channel

Hospital Pharmacies:

Hospital pharmacies play a crucial role in the distribution of overactive bladder medications, primarily catering to patients admitted for other medical conditions requiring comprehensive care. The presence of specialized healthcare professionals in hospital settings allows for tailored drug therapy management, often involving a multidisciplinary team approach to address complex medical needs. Hospital pharmacies are essential for ensuring that patients receive the appropriate medications in a timely manner, especially for those requiring immediate treatment for acute symptoms. As hospitals strive to improve patient outcomes and enhance the efficiency of care delivery, the significance of hospital pharmacies in the OAB medication market continues to grow.

Retail Pharmacies:

Retail pharmacies serve as the most accessible point of distribution for overactive bladder medications, offering patients the convenience of filling prescriptions close to home. Retail pharmacies are crucial for educating patients on medication use, potential side effects, and adherence strategies, thereby playing a key role in treatment success. The competition among retail pharmacy chains has intensified, leading to promotional offers, loyalty programs, and improved customer service aimed at attracting OAB patients. As patient preferences shift towards convenience and ease of access, retail pharmacies are expected to maintain a significant share of the OAB medication distribution channel, particularly as more individuals seek treatment for their bladder health issues.

Online Pharmacies:

The rise of online pharmacies has transformed the landscape of pharmaceutical distribution, offering patients an alternative means to access overactive bladder medications. The convenience of ordering medications online, coupled with the ability to maintain privacy regarding sensitive health issues like OAB, has led to increased utilization of online services. This distribution channel has gained particular traction during the COVID-19 pandemic, as many patients prefer to avoid in-person visits to pharmacies. The online pharmacy market is characterized by competitive pricing, home delivery options, and various payment methods, which appeal to tech-savvy consumers. As digital health continues to evolve, online pharmacies are expected to capture an increasing market share in the distribution of OAB medications.

Others:

The "Others" distribution channel segment includes specialized clinics and home healthcare services that provide overactive bladder medications directly to patients. These settings often focus on personalized care and may involve a more comprehensive approach to managing OAB symptoms, including counseling, lifestyle modifications, and medication management. While this segment does not dominate the market, it is crucial in addressing the needs of patients seeking targeted and individualized care. The growth of telemedicine and home healthcare services presents opportunities for this segment to expand, allowing patients to receive necessary medications and support in a comfortable environment.

By Ingredient Type

Oxybutynin:

Oxybutynin, a widely recognized anticholinergic agent, has been one of the cornerstone treatments for overactive bladder for many years. It operates by inhibiting involuntary contractions of the bladder, thus enhancing urinary control and minimizing urgency. Oxybutynin is available in various formulations, including immediate-release, extended-release, and transdermal patches, giving patients flexibility in managing their symptoms. Despite its efficacy, some patients may experience side effects, such as dry mouth and constipation, leading to decreased adherence. Nevertheless, oxybutynin remains a popular choice among healthcare providers due to its proven track record and extensive clinical experience supporting its use.

Tolterodine:

Tolterodine is another anticholinergic agent utilized for OAB treatment, noted for its selective action on the bladder musculature. Its formulation allows for extended-release dosing, improving patient compliance and minimizing side effects associated with immediate-release formulations. Tolterodine provides effective symptom relief while being well-tolerated by many patients, making it a favored option among practitioners. The ongoing research into the comparative effectiveness of tolterodine against newer medications, such as mirabegron, is essential for understanding its place in current OAB treatment guidelines. With increasing awareness of OAB, tolterodine's market presence is anticipated to remain strong.

Solifenacin:

Solifenacin is a selective muscarinic antagonist that has gained popularity in treating overactive bladder due to its improved efficacy and tolerability compared to older anticholinergics. It provides effective symptom control while minimizing side effects, making it a suitable option for many patients. Its once-daily dosing regimen enhances patient compliance, and its ability to reduce urgency and frequency without causing significant dry mouth has contributed to its preferred use among clinicians. As more studies continue to affirm solifenacin's benefits, its market share is expected to increase, particularly among patients seeking effective and well-tolerated treatment options.

Trospium:

Trospium chloride is an anticholinergic compound that is utilized for managing symptoms of overactive bladder. It is unique among its class due to its quaternary ammonium structure, which limits central nervous system penetration and reduces side effects like cognitive impairment. Trospium is particularly advantageous for elderly patients who may be sensitive to the side effects of other anticholinergics. With formulations available for both immediate and extended-release, trospium offers flexibility in dosing schedules, appealing to various patient needs. As the awareness of the importance of individualized treatment escalates, trospium's market presence is likely to grow, particularly in geriatric populations.

Others:

The "Others" ingredient type category includes various emerging compounds and combinations that are being explored for their potential effectiveness in managing overactive bladder symptoms. This segment may encompass newer agents in clinical trials, herbal remedies, and dietary supplements that claim to alleviate OAB symptoms. While these alternatives currently hold a smaller market share, the interest in natural and holistic treatment approaches is on the rise, driven by patient preferences for non-pharmacological interventions. As research continues to validate the safety and efficacy of these options, they may gain traction and contribute to a more diverse range of treatments available for OAB management.

By Region

The Overactive Bladder Medication market exhibits considerable regional variations, with North America holding the largest market share, accounting for over 40% of the total revenue. The United States, in particular, drives this segment due to its well-established healthcare infrastructure, high prevalence of OAB, and extensive access to advanced treatment options. The growing awareness of OAB and supportive healthcare policies have further bolstered the market in this region. Additionally, the presence of key pharmaceutical companies and ongoing research initiatives contribute to the ongoing market expansion within North America. The region is expected to witness a steady CAGR as more patients seek effective management strategies for their bladder health.

Europe stands as the second-largest market for OAB medications, driven by rising healthcare expenditure and increasing awareness regarding bladder health issues. The European market is characterized by a diverse range of treatment options and the availability of advanced therapies, with countries like Germany, France, and the UK leading in market share. Moreover, the increasing aging population in Europe amplifies the demand for effective treatments, as older adults are more susceptible to OAB. The European market is projected to grow at a moderate CAGR, supported by innovative drug development and enhanced patient education initiatives. In contrast, the Asia Pacific region is anticipated to experience the highest growth rate during the forecast period due to a rapidly aging population, increasing healthcare access, and rising awareness of overactive bladder conditions.

Opportunities

The Overactive Bladder Medication market presents numerous opportunities for growth, particularly due to the increasing demand for effective management strategies. The rising prevalence of overactive bladder in conjunction with the aging population offers a substantial market potential for pharmaceutical companies to invest in research and development. The growing emphasis on personalized medicine is another opportunity that allows for the development of targeted therapies tailored to individual patient needs. Furthermore, the integration of digital technology in healthcare, including telehealth services and mobile health applications, creates avenues for better patient engagement and adherence to treatment protocols. These innovations enable healthcare providers to monitor patient progress remotely, ensuring timely adjustments to therapy as needed and ultimately improving patient outcomes.

Additionally, untapped markets in developing regions present a wealth of opportunities for industry players. As awareness regarding overactive bladder continues to grow globally, the demand for effective treatment options in regions such as Latin America, the Middle East, and Africa is projected to rise significantly. Pharmaceutical companies have the chance to expand their market presence in these regions by establishing partnerships with local healthcare providers and introducing affordable medication alternatives. Moreover, the potential for collaborations in research and development with academic institutions may yield breakthroughs in OAB treatments, paving the way for innovative solutions that can address the needs of diverse patient populations.

Threats

Despite the promising outlook for the Overactive Bladder Medication market, several threats could hinder its growth trajectory. The emergence of generic medications poses a significant challenge to established pharmaceutical companies, as increased competition can lead to price erosion and reduced profit margins. Patients may opt for lower-cost generic alternatives, impacting the sales of branded medications. Additionally, the rising trend of self-medication and reliance on non-prescription treatments, such as dietary supplements and herbal remedies, could divert patients away from conventional pharmacological therapies, further affecting market dynamics. The need for continuous innovation and the rapid pace of technological advancements necessitate that companies remain agile to adapt to changing consumer preferences and market conditions.

Furthermore, regulatory hurdles and stringent approval processes for new medications can slow down the introduction of innovative therapies into the market. Companies must navigate complex clinical trials and meet extensive regulatory requirements, which can delay product launches and limit market access. Additionally, shifts in healthcare policies, particularly concerning reimbursement rates and insurance coverage for OAB treatments, may impact market sustainability and patient affordability. Overall, addressing these threats through strategic planning and adaptive measures will be critical for stakeholders in the OAB medication market.

Competitor Outlook

• Astellas Pharma Inc.
• Pfizer Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Ferring Pharmaceuticals Inc.
• Sigma-Tau Pharmaceuticals, Inc.
• Mylan N.V.
• Hikma Pharmaceuticals PLC
• Endo International plc
• Urovant Sciences Ltd.
• Hisamitsu Pharmaceutical Co., Inc.
• Medtronic
• Alva Pharmaceuticals, LLC

The competitive landscape of the Overactive Bladder Medication market is characterized by a mix of established players and emerging companies striving to innovate and capture market share. Major pharmaceutical companies such as Astellas Pharma and Pfizer dominate the market with their robust portfolios of anticholinergic medications and novel treatment options like mirabegron. These companies invest significantly in research and development, focusing on expanding their product lines and improving existing therapies to address the diverse needs of patients with overactive bladder. Additionally, strategic partnerships and collaborations with healthcare providers and academic institutions enable these companies to leverage their expertise and enhance market presence.

Emerging players like Urovant Sciences and Alva Pharmaceuticals are also gaining traction within the OAB medication landscape through innovative product offerings and targeted marketing strategies. These companies often focus on niche markets and introduce unique therapeutic solutions that cater to specific patient populations. The increasing interest in personalized medicine drives competition among these players, as they seek to develop tailored therapies that improve patient outcomes. As the market continues to evolve, smaller companies can carve out a competitive advantage through agility and adaptability in response to shifting consumer demands.

Furthermore, companies like AbbVie and Teva Pharmaceutical are exploring biosimilar and generic pathways to expand their reach and enhance affordability for patients seeking treatment. The trend toward generics can disrupt the market dynamics as established brands face competition from lower-cost alternatives. To counteract this, large pharmaceutical companies are increasingly focusing on value-added services, such as patient support programs and adherence initiatives, to maintain strong relationships with healthcare providers and patients. Overall, the competitive landscape of the Overactive Bladder Medication market is dynamic and multifaceted, with major players and emerging companies continuously striving to innovate and respond to ever-changing market conditions.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Medtronic
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Mylan N.V.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Astellas Pharma Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Urovant Sciences Ltd.
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Endo International plc
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Alva Pharmaceuticals, LLC
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Hikma Pharmaceuticals PLC
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bristol-Myers Squibb Company
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Ferring Pharmaceuticals Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Sigma-Tau Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Hisamitsu Pharmaceutical Co., Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Teva Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Overactive Bladder Medication Market, By Application
    • 6.1.1 Idiopathic Overactive Bladder
    • 6.1.2 Neurogenic Overactive Bladder
    • 6.1.3 Others
  • 6.2 Overactive Bladder Medication Market, By Product Type
    • 6.2.1 Anticholinergics
    • 6.2.2 Mirabegron
    • 6.2.3 Alpha Blockers
    • 6.2.4 Botox
    • 6.2.5 Others
  • 6.3 Overactive Bladder Medication Market, By Ingredient Type
    • 6.3.1 Oxybutynin
    • 6.3.2 Tolterodine
    • 6.3.3 Solifenacin
    • 6.3.4 Trospium
    • 6.3.5 Others
  • 6.4 Overactive Bladder Medication Market, By Distribution Channel
    • 6.4.1 Hospital Pharmacies
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Overactive Bladder Medication Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Overactive Bladder Medication market is categorized based on

By Product Type

• Anticholinergics
• Mirabegron
• Alpha Blockers
• Botox
• Others

By Application

• Idiopathic Overactive Bladder
• Neurogenic Overactive Bladder
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

By Ingredient Type

• Oxybutynin
• Tolterodine
• Solifenacin
• Trospium
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Astellas Pharma Inc.
• Pfizer Inc.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Sanofi S.A.
• Bristol-Myers Squibb Company
• Ferring Pharmaceuticals Inc.
• Sigma-Tau Pharmaceuticals, Inc.
• Mylan N.V.
• Hikma Pharmaceuticals PLC
• Endo International plc
• Urovant Sciences Ltd.
• Hisamitsu Pharmaceutical Co., Inc.
• Medtronic
• Alva Pharmaceuticals, LLC